Autopsy report · NCT06145399

A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer

“No accruals”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Early Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Breast Carcinoma; Metastatic Breast Cancer; Metastatic Breast Carcinoma; Female Breast Cancer

Interventions

18F-FDG PET/CT; [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone PET Imaging; 18F-FDHT

Participants

0

Trials that died the same way

• Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal Cancer
  “No accrual” (96% match in meaning)
• Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
  “0 accrual” (80% match in meaning)
• Dose Escalated Proton Beam Therapy or Photon Therapy for Esophageal Cancer
  “non-accrual” (77% match in meaning)
• Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme
  “poor accrual” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.